MINT-LOSARTAN/HCTZ TABLET

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE

Fáanlegur frá:

MINT PHARMACEUTICALS INC

ATC númer:

C09DA01

INN (Alþjóðlegt nafn):

LOSARTAN AND DIURETICS

Skammtar:

50MG; 12.5MG

Lyfjaform:

TABLET

Samsetning:

LOSARTAN POTASSIUM 50MG; HYDROCHLOROTHIAZIDE 12.5MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

30/100/1000

Gerð lyfseðils:

Prescription

Lækningarsvæði:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Vörulýsing:

Active ingredient group (AIG) number: 0233168001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2012-07-27

Vara einkenni

_MINT-LOSARTAN/HCTZ and MINT-LOSARTAN/HCTZ_
_ _
_DS _
_(losartan potassium and hydrochlorothiazide) _
_Page 1 of 44_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MINT-LOSARTAN/HCTZ
losartan potassium and hydrochlorothiazide tablets
Tablets, 50 mg / 12.5 mg and 100 mg / 12.5 mg, Oral
Pr
MINT-LOSARTAN/HCTZ DS
losartan potassium and hydrochlorothiazide tablets
Tablets, 100 mg / 25 mg, Oral
House Standard
Angiotensin II Receptor Antagonist and Diuretic
MINT PHARMACEUTICALS INC.
6575 Davand Drive
Mississauga, Ontario
L5T 2M3
Date of Initial Authorization:
JUL 27, 2012
Date of Revision:
FEB 14, 2023
Submission Control Number: 267752
_MINT-LOSARTAN/HCTZ and MINT-LOSARTAN/HCTZ_
_ _
_DS _
_(losartan potassium and hydrochlorothiazide) _
_Page 2 of 44_
_ _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Respiratory
02/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
....................................................................................................................
4
1.2
Geriatrics
....................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 4
4
DOSAGE AND ADMINISTRATION
...................................................................